Krystal Biotech - נכסים נקיים למניה בודדת KRYS

The historical price action of Krystal Biotech, Inc. (KRYS) demonstrates the success of this biotech pioneer in treating rare skin pathologies, whose unique patents on viral gene delivery block competitors from entering the market. The current indicator stands at 45.70, while the company balances risks by utilizing revenues from certified treatments to develop the aesthetics sector. Sales stability is supported by the humanitarian status of the medicine, which offsets the impact of global trade conflicts.

Investors determine the capital safety margin by analyzing net assets per share. For Krystal Biotech, Inc. (KRYS), this resource is critical during the commercialization of the monopoly drug VYJUVEK. The BVPS valuation reflects the difference between all of the issuer's assets and liabilities. The growth of this curve confirms the business's internal resilience to market shocks. This asset falls into the category of high-tech growth with fundamental support.